Trupharma Patent-Cliff Exposure & CMS Drug Spending Portfolio

Trupharma (US): 4 reconciled FDA prescription therapies, $12.0M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$12.0M
2024 Medicare Part D Spend$6.1M
2024 Medicaid Spend$5.9M
California HCAI SB 17 Filings2 WAC filings (max 21.1% 2-yr change)